Rezafungin Intravenous Infusion for Adults

Who can administer

May be administered by registered competent doctor or nurse/midwife

Important information

• Reserve antimicrobial:  Restricted for indications in the antimicrobial prescribing guidelines, or following approval by microbiology/infectious diseases 

Available preparations

REZZAYO 200mg vial (Mundipharma pharmaceuticals) 

Reconstitution

Water for injection
9.5 mL per 200mg vial (produces a 20mg per ml solution). 

• Do NOT shake. To avoid foaming it is recommended that diluent should be added carefully, along the walls of the vials gently swirling the vial for up to 5 minutes until the powder is dissolved. The solution should be a clear, colourless to pale yellow colour.
• The reconstituted solution should be visually inspected for particulate matter and/or discolouration. If irregularities are found, do not use the vial.  

Dilute further prior to administration

Infusion fluids

Sodium chloride 0.9% or Glucose 5%

Methods of intravenous administration

Intermittent intravenous infusion

• Add required dose to 250mL infusion fluid
• Administer over 60 minutes using an electronically controlled infusion device
• Administer over 180 minutes if the patient experiences an infusion-related reaction (see monitoring section below) 

Dose in adults

Invasive candidiasis 

• Give a single 400mg (loading dose) on Day 1, followed by 200mg (maintenance dose) on Day 8 and once weekly thereafter
• The duration of treatment should be based upon the patient's clinical and microbiological response. In general, antifungal therapy should continue for at least 14 days after the last positive culture
• See Under Further Information below re missed or omitted doses

Hepatic impairment

• No dosage adjustment required

Renal impairment

• No dosage adjustment required

Monitoring

Acute reactions

• Infusion related reactions including flushing, sensation of warmth, nausea, chest tightness, pyrexia, hypotension, skin changes including erythema, rash, phototoxicity, urticaria, wheezing and tremor
• If infusion-related reactions occur, stop treatment and restart at a slower rate once symptoms have resolved

Note: contains polysorbate 80 as an excipient which may cause hypersensitivity reactions including anaphylaxis.

Monitor

• Hepatic function
• Monitor for infusion-related reactions for the duration of the infusion
• Advise patients to avoid sun exposure and other sources of UV radiation without adequate protection during treatment and for 7 days after the last dose of rezafungin

Further information

• If a scheduled dose is missed (not given on the assigned day) the missed dose should be administered as soon as possible. 
• If the missed dose is administered within 3 days of the assigned day, the next weekly dose may be given on schedule. 
• If the missed dose is administered more than 3 days after the assigned day, the dosing schedule should be revised to ensure there are at least 4 days before the next dose. 
• If administration is restarted after at least 2 weeks of missed dosing, the dosing should be started again at the 400 mg loading dose.

Storage

Store below 25⁰C

References

REZZAYO (Mundipharma Pharmaceuticals) SPC 01/04/2025

1. Injectable Medicines Guide, Downloaded from Medusa, 03/11/2025

Therapeutic classification

Antifungal agent